These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 21294362)

  • 21. [Legislation by BMGS on evaluation of cost effectiveness].
    GFB
    Chirurg; 2004 Mar; 75(3):M76. PubMed ID: 15080093
    [No Abstract]   [Full Text] [Related]  

  • 22. [HTA-Perspective: Challenges in the early assessment of new oncological drugs].
    Wild C; Nachtnebel A
    Z Evid Fortbild Qual Gesundhwes; 2013; 107(2):129-35. PubMed ID: 23663907
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cancer Drugs Fund of minimal benefit.
    Burki TK
    Lancet Oncol; 2017 Jun; 18(6):e305. PubMed ID: 28483412
    [No Abstract]   [Full Text] [Related]  

  • 24. [Investigation today for practice tomorrow].
    Klein H
    Dtsch Med Wochenschr; 2013 May; 138(18):933. PubMed ID: 23613370
    [No Abstract]   [Full Text] [Related]  

  • 25. [Physicians and insurance may collaborate on therapy].
    MMW Fortschr Med; 2006 Aug; 148(31-32):45. PubMed ID: 16937879
    [No Abstract]   [Full Text] [Related]  

  • 26. Free drugs in clinical trials and their potential cost saving impact on the National Health Service: a retrospective cost analysis in Italy.
    Grossi F; Genova C; Gaitan ND; Dal Bello MG; Rijavec E; Barletta G; Sini C; Donato C; Beltramini S; Pronzato P; Porcile G; Boccardo F; Walzer S
    Lung Cancer; 2013 Aug; 81(2):236-40. PubMed ID: 23648072
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Individual therapeutic experiments. Ethical problems exemplified in oncology].
    Rippe KP
    Internist (Berl); 1999 Nov; 40(11):1243-6. PubMed ID: 10636722
    [No Abstract]   [Full Text] [Related]  

  • 28. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
    Marchetti M; Caruggi M; Colombo G
    Clin Ther; 2004 Sep; 26(9):1546-61. PubMed ID: 15531017
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Health policy: Putting a price on cancer.
    Sullivan R; Aggarwal A
    Nat Rev Clin Oncol; 2016 Mar; 13(3):137-8. PubMed ID: 26856742
    [No Abstract]   [Full Text] [Related]  

  • 30. [Scope of the contract for drug therapy. Rebate contracts also for original drugs].
    MMW Fortschr Med; 2009 Jul; 151(30-33):80. PubMed ID: 19722473
    [No Abstract]   [Full Text] [Related]  

  • 31. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [New cost saving legislation for drugs. National health insurance carriers do not want to believe Ulla Schmidt}].
    MMW Fortschr Med; 2006 Feb; 148(5):45. PubMed ID: 16518939
    [No Abstract]   [Full Text] [Related]  

  • 33. Many new cancer drugs in the United Kingdom are facing negative NICE rulings.
    Low E;
    J Clin Oncol; 2007 Jun; 25(18):2635-6; author reply 2637-8. PubMed ID: 17577049
    [No Abstract]   [Full Text] [Related]  

  • 34. European perspective on the costs and cost-effectiveness of cancer therapies.
    Drummond MF; Mason AR
    J Clin Oncol; 2007 Jan; 25(2):191-5. PubMed ID: 17210939
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potential clinical and economic impact of nonadherence with osteoporosis medications.
    Hiligsmann M; Rabenda V; Gathon HJ; Ethgen O; Reginster JY
    Calcif Tissue Int; 2010 Mar; 86(3):202-10. PubMed ID: 20205345
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pharmacoeconomy in acne--evaluation of benefit and economics].
    Radtke MA; Schäfer I; Augustin M
    J Dtsch Dermatol Ges; 2010 Mar; 8 Suppl 1():S105-14. PubMed ID: 20482687
    [TBL] [Abstract][Full Text] [Related]  

  • 37. United healthcare, five oncology practices try bundled payments.
    Goozner M
    J Natl Cancer Inst; 2011 Jan; 103(1):8-10. PubMed ID: 21169535
    [No Abstract]   [Full Text] [Related]  

  • 38. [Millions of old cost burdens. The time bomb of overdue drug budgets].
    Bossmann A
    Chirurg; 1998 Apr; 69(4):suppl 116-8. PubMed ID: 9612626
    [No Abstract]   [Full Text] [Related]  

  • 39. [New, expensive antidiabetics for the treatment of type-2 diabetes--pro].
    Müller-Wieland D
    Dtsch Med Wochenschr; 2010 May; 135(18):922. PubMed ID: 20425678
    [No Abstract]   [Full Text] [Related]  

  • 40. [Bonus in reduced prescription costs. Would you comply?].
    Schmidt K
    MMW Fortschr Med; 2002 Sep; 144(39):45-6. PubMed ID: 12422688
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.